I keep seeing people say "tirz works better because it hits two receptors instead of one" but I've never seen a really thorough explanation of WHY the GIP component adds so much. Can someone who actually understands the pharmacology break this down?

Specifically:

• What does GIP receptor agonism do that GLP-1 agonism alone doesn't?
• Why was GIP considered a weird target initially? (I've read that some researchers thought GIP ANTAGONISM would be better for obesity)
• Is there synergy between the two pathways or is it purely additive?

I'm a biochem grad student so don't dumb it down too much 😊

Great questions. I'll try to be thorough since you've got the background for it.

GIP Receptor Agonism — What it adds:

GIP (glucose-dependent insulinotropic polypeptide) was historically called "gastric inhibitory polypeptide" and was considered an incretin that mainly potentiated insulin secretion. But GIP receptors are expressed far more broadly than originally appreciated:

1. Adipose tissue: GIP receptors on adipocytes regulate lipid storage, lipolysis, and adipose tissue blood flow. GIP agonism appears to improve adipose tissue "health" — promoting proper lipid storage and reducing ectopic fat deposition (liver, visceral, intramuscular). This is likely why tirz shows superior triglyceride and liver fat reductions compared to sema.
2. CNS: GIPR expression in the hypothalamus (particularly the ARC and PVN) modulates feeding behavior through pathways that are partially distinct from GLP-1R signaling. The net effect: GIP and GLP-1 suppress appetite through complementary but non-identical neuronal circuits.
3. Pancreatic β-cells: Both GIP and GLP-1 are incretins that potentiate glucose-dependent insulin secretion, but through distinct intracellular signaling cascades (cAMP/PKA vs cAMP/Epac2 predominance). Dual agonism provides more robust insulin secretion improvement than either alone.
4. Bone: GIP has anabolic effects on bone metabolism (stimulates osteoblast activity). This may partially offset the bone density concerns with weight loss.

The GIP Paradox:

You're right that this was controversial. In obesity, GIP signaling is dysregulated — obese individuals have blunted GIP responses and some researchers hypothesized that GIP PROMOTED fat storage (the "thrifty" hypothesis). This led to the counterintuitive prediction that GIP antagonism might be anti-obesity.

Amgen actually developed a GIPR antagonist (AMG-133, now maridebart cafraglutide) that combined GIP antagonism with GLP-1 agonism. It also showed significant weight loss in early trials.

The current understanding is that the system is more nuanced — chronic pharmacological GIP agonism at supraphysiological levels (as with tirzepatide) may actually desensitize/downregulate GIPR in a way that produces net effects similar to antagonism in peripheral tissues while maintaining agonist effects centrally. This is the "functional selectivity" or "biased agonism" hypothesis.

Synergy vs Additive:

The evidence points toward genuine synergy, not just additive effects. In preclinical models, dual GIP/GLP-1 agonism produces weight loss greater than the sum of either agonist alone. The proposed mechanism involves:

• GIP-mediated enhancement of GLP-1 receptor sensitivity (cross-receptor potentiation)
• Complementary effects on gastric emptying (GLP-1 slows it, GIP modulates acid/enzyme secretion)
• Convergent but distinct CNS appetite suppression pathways creating a more "complete" satiety signal

Finan et al. (2013) in Nature Medicine was the landmark paper that first demonstrated this synergistic effect with a dual agonist peptide, which eventually led to tirzepatide's development at Lilly.¹

¹ Finan B, et al. "A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents." Nat Med. 2015;21(1):27-36.

This is exactly what I was looking for, thank you! The functional selectivity hypothesis is fascinating — so the idea is that chronic high-dose GIP agonism might functionally LOOK like antagonism at peripheral GIPR? That's wild.

Follow-up: does this mean the AMG-133/maridebart approach (GIP antagonism + GLP-1 agonism) might ultimately produce similar outcomes to tirzepatide (GIP agonism + GLP-1 agonism) through convergent downstream effects?

That's the million-dollar question (literally — whoever's right wins the next wave of the obesity market). The early maridebart data showed impressive weight loss (~14-15% at 12 weeks, which if sustained would project to very high numbers), but it's hard to directly compare across trials with different populations and durations.

If the convergent mechanism hypothesis is correct, then yes — agonism and antagonism at GIPR might produce similar metabolic endpoints through different molecular paths. It would be one of the more elegant pharmacological paradoxes in recent drug development.

We won't know for sure until we have head-to-head data, which is probably years away.

For the non-biochem people reading this (like me):

GLP-1 drugs = one key that turns one lock
Tirzepatide = two keys that turn two different locks at the same time

The two locks control overlapping but different things in your body, and turning them both produces a bigger effect than turning either one alone. Also one of the locks (GIP) does cool stuff with your fat cells and brain that the other lock (GLP-1) can't do on its own.

That's my understanding anyway. Roy please correct me if I butchered it 😅